SE9804314D0 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
SE9804314D0
SE9804314D0 SE9804314A SE9804314A SE9804314D0 SE 9804314 D0 SE9804314 D0 SE 9804314D0 SE 9804314 A SE9804314 A SE 9804314A SE 9804314 A SE9804314 A SE 9804314A SE 9804314 D0 SE9804314 D0 SE 9804314D0
Authority
SE
Sweden
Prior art keywords
gt
lt
invention
related
dosage forms
Prior art date
Application number
SE9804314A
Other languages
Swedish (sv)
Inventor
Arne Eek
Lars Josefsson
Per Johan Lundberg
Aake Pilbrant
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9804314A priority Critical patent/SE9804314D0/en
Publication of SE9804314D0 publication Critical patent/SE9804314D0/en

Links

Abstract

This invention is related to new oral pharmaceutical dosage forms comprising a proton pump inhibitor, i.e. a H<+>, K<+> -ATPase inhibitor, a gastric antisecretory prostaglandin analogue compound, and optionally an additional drug such as a calcium channel blocking agent, especially for use in the treatment and prophylaxis of gastrointestinal disorders. More specifically the invention is related to new dosage forms comprising omeprazole and misoprostol. The invention is also related to a combination of the three categories of drugs, i.e. the H<+>, K<+> -ATPase inhibitor, the gastric antisecretory prostaglandin analogue, and the calcium channel blocking agent. Furthermore, the invention refers to a method for the manufacture of the described dosage forms and their use in medicine, as well as blister packs comprising these medicaments.
SE9804314A 1998-12-14 1998-12-14 New pharmaceutical formulation SE9804314D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SE9804314A SE9804314D0 (en) 1998-12-14 1998-12-14 New pharmaceutical formulation

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
SE9804314A SE9804314D0 (en) 1998-12-14 1998-12-14 New pharmaceutical formulation
EP19990963820 EP1150677A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
BR9916224-5A BR9916224A (en) 1998-12-14 1999-12-10 An oral pharmaceutical dosage form, processes for the manufacture of a fixed dosage form for the treatment and prophylaxis of gastrointestinal disorders, and to prevent gastrointestinal side-effects, use of a dosage form, combination, and packaging bulb type
JP2000587768A JP2002532425A (en) 1998-12-14 1999-12-10 New pharmaceutical formulations
IL14338699A IL143386D0 (en) 1998-12-14 1999-12-10 Pharmaceutical dosage form comprising a h+, k+ -atpase inhibitor and gastric antisecretory prostaglandin analogue compound
AU20186/00A AU776079B2 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
CN 99816118 CN1334731A (en) 1998-12-14 1999-12-10 Pharmaceutical formulation
PCT/SE1999/002315 WO2000035448A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
NZ51199999A NZ511999A (en) 1998-12-14 1999-12-10 Pharmaceutical formulation comprising a H+,K+-ATPase inhibitor and a gastric antisecretory prostaglandin analogue
CA 2352613 CA2352613A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
ZA200104273A ZA200104273B (en) 1998-12-14 2001-05-24 New pharmaceutical formulation.
NO20012915A NO20012915L (en) 1998-12-14 2001-06-13 New pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SE9804314D0 true SE9804314D0 (en) 1998-12-14

Family

ID=20413648

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804314A SE9804314D0 (en) 1998-12-14 1998-12-14 New pharmaceutical formulation

Country Status (12)

Country Link
EP (1) EP1150677A1 (en)
JP (1) JP2002532425A (en)
CN (1) CN1334731A (en)
AU (1) AU776079B2 (en)
BR (1) BR9916224A (en)
CA (1) CA2352613A1 (en)
IL (1) IL143386D0 (en)
NO (1) NO20012915L (en)
NZ (1) NZ511999A (en)
SE (1) SE9804314D0 (en)
WO (1) WO2000035448A1 (en)
ZA (1) ZA200104273B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US8268333B2 (en) 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
ITMI20020515A1 (en) * 2002-03-12 2003-09-12 Jagotec Ag System for rilasco controlled by one or more 'active ingredients
EP1607088B1 (en) * 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
RU2005137865A (en) * 2003-06-06 2006-06-10 Такеда Фармасьютикал Компани Лимитед (Jp) solid prerarat
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2005289867A (en) * 2004-03-31 2005-10-20 Lintec Corp Agent for peroral administration
CN1311824C (en) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 Enteric coated micro particle preparation of omeprazole and its preparation method
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2371658T3 (en) 2005-04-12 2012-01-05 Sucampo Ag Combined use of prostaglandine composite and inhibitor of the pump of protons for the treatment of gastrointestinal disorders.
EP1987820A1 (en) * 2007-05-04 2008-11-05 Christian Fiala, Ph. D. Slow release misoprostol for obstetric and/or gynaecological applications
CN102078615A (en) * 2011-01-21 2011-06-01 北京华禧联合科技发展有限公司 Composition of proton pump inhibitor and gastric mucosa protective agent
JP2017522321A (en) * 2014-07-17 2017-08-10 ダウ グローバル テクノロジーズ エルエルシー Ethylcellulose dispersion and film
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2018205790A1 (en) 2017-01-04 2019-07-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Also Published As

Publication number Publication date
BR9916224A (en) 2001-09-04
CA2352613A1 (en) 2000-06-22
WO2000035448A1 (en) 2000-06-22
JP2002532425A (en) 2002-10-02
CN1334731A (en) 2002-02-06
NZ511999A (en) 2002-10-25
IL143386D0 (en) 2002-11-10
EP1150677A1 (en) 2001-11-07
NO20012915L (en) 2001-08-13
AU776079B2 (en) 2004-08-26
ZA200104273B (en) 2002-08-26
AU2018600A (en) 2000-07-03
NO20012915D0 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
CA2260943C (en) Formulation of 5-ht agonists
TW590778B (en) Pharmaceutical composition of topiramate
US4446140A (en) Method and composition for treating mouth pain
ID29837A (en) Oral dosage formulations that melt instantly
NZ531651A (en) Phenethanolamine derivatives for treatment of respiratory diseases
SA2048B1 (en) Loss prevention and restoration of bone mass by Meddat Prostaglandin prostaglandin agonists certain
RU2000132711A (en) Formulations for administration of anti-inflammatory, especially antiseptic agents and / or substances promoting the healing of wounds to the upper respiratory tract and / or ear
NO20061925L (en) A pharmaceutical composition for preventing overdose or abuse
NO334301B1 (en) Anhydrous crystalline tiotropium bromide, processes for their preparation, pharmaceutical and uses thereof for the preparation of a medicament for the treatment of diseases
CY1107592T1 (en) ORAL sublingual effervescent agent
SE0301700D0 (en) Novel compounds
ES2196556T3 (en) Pellet formulation for treating intestinal tract.
NO20120524A1 (en) Use of BAFF-related antibody for the preparation of medicaments against lymphoproliferative diseases
GR1002397B (en) Pharmaceutical composition containing a guanidinothiazole compound and antacids.
NO20051962L (en) Fenetanolaminderivater for treating respiratory diseases
NO941894L (en) Mixtures with delayed release of risedronate
NO20100777L (en) Quinazolinones, such compounds for use as medicaments, pharmaceutical compositions containing them and to the use thereof for the preparation of medicament for treating disease
IS6557A (en) Combination therapies of antihypertensive agents and agents that inhibit angiogenesis
AR035500A1 (en) Chlorpromazine and pentamidine use for the manufacture of medicines, pharmaceutical composition and pharmaceutical pack comprising chlorpromazine and pentamidine.
EE05581B1 (en) A pharmaceutical solution of aripiprazole for oral administration
NO328890B1 (en) Pyrrolopyrimidines, their use and pharmaceutical compositions comprising such compound
NZ535229A (en) Aryl 5-thio-beta-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
NO332637B1 (en) Use of R - (+) - 2- (3-diisopropylamino-1-phenylpropyl) -4-hydroxymethyl-fenylisosmørsyreester- hydrogen fumarate for manufacture of a medicament for the treatment of urinary incontinence and other spasmogenic diseases and pharmaceutical formulation thereof
PE07032003A1 (en) Inhibitors 17b-hydroxysteroid dehydrogenase type 3
NO924209L (en) Dosage Form for tilfoersel of an anti-parkinsonian agent